Parmax Pharma Stock: price and insider trades · India
Parmax Pharma: what insiders have been doing
Parmax Pharma is a listed company. Its directors and officers file their transactions with SEBI (PIT + SAST). Over the twelve months to 8 November 2026, 4 filings were filed, from 4 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
No insider has bought Parmax Pharma shares on the open market in the past twelve months. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade.
Compared with its exchange (1,984 companies, median 4 filings), a count of 4 filings is typical.
This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 670,380 shares@ ₹35.004.52% mcap100.0% of flowEquityOff MarketSEBI:b9f2385cb95c704a2954274760691c33ad574af1
- 700 shares@ ₹35.000.0047% mcap100.0% of flowEquityOff MarketSEBI:1c8e325b1e267deec447abac25b87d848daceced
- 481,370 shares@ ₹35.003.25% mcap100.0% of flowEquityOff MarketSEBI:b11f205d9bff23edde73325d844d95af335edaba
- 300,000 shares-TransferSEBI:e2b26837e017eb31f6f201c83ff6e4f7463b18cc
4 of 4 declarations
About Parmax Pharma
Parmax Pharma is a company specialized in the pharmaceutical sector, listed on the XBOM. It focuses on developing innovative solutions for the treatment of various diseases.